Search form

 

Press Releases


Axcan submits FDA amendment to its new drug application for HELIZIDE


Mar 29, 2006 - 11:59 ET

MONT-SAINT-HILAIRE, QC, March 29 - Axcan Pharma Inc.
(NASDAQ: AXCA - TSX: AXP) announced today that it has submitted an amendment
to its New Drug Application ("NDA") for HELIZIDE, its patented capsule therapy
for the eradication of Helicobacter pylori. Each HELIZIDE capsule contains
biskalcitrate potassium (140 mg), metronidazole (125 mg) and tetracycline
hydrochloride (125 mg). This amendment addresses earlier FDA questions related
to manufacturing issues and is the final step before potential approval of the
drug. Phase III clinical data have already been submitted to the FDA, and no
safety or efficacy issues were raised.

"We are very pleased to be at this stage, as results of our Phase III
studies indicate that HELIZIDE is effective in eradicating Helicobacter
pylori. Furthermore, it is well known that resistance is an increasing issue,
so it is extremely positive to have some excellent data confirming that
HELIZIDE is also successful in patients who are resistant to some of the drugs
used in current therapies," said Frank Verwiel, M.D., President and Chief
Executive Officer of Axcan. "Based on the review time needed by the FDA, we
could launch HELIZIDE in the United States as early as the first half of
calendar 2007. The U.S. patent on the use of a double capsule for the
administration of the HELIZIDE triple therapy will expire in December 2018,
which gives us ample time to penetrate the $150 million U.S. market. In
parallel, we are currently working on filing in the European Union," he
concluded.

HELIZIDE PHASE III CLINICAL STUDIES

The Phase III North American trials conducted on 275 patients with a
history of duodenal ulcer compared Axcan's HELIZIDE regimen (3 capsules given
4 times a day) given in combination with two daily doses of
20 mg of omeprazole, to the widely used OAC combination (20 mg of omeprazole,
1 g of amoxicillin and 500 mg of clarithromycin, all given twice a day). On an
intent-to-treat basis, the eradication rates were 88% and 83%, respectively,
in favor of HELIZIDE.

In the group of patients with a metronidazole-resistant strain of
Helicobacter pylori (41% of patients at the start of the study), Helicobacter
pylori eradication was achieved in 80% of patients treated with HELIZIDE. In
the group of clarithromycin-resistant patients (12% of patients at the
beginning of the study), only 21% were successfully treated with OAC. These
results confirm that HELIZIDE has the potential to be used as a first-line
therapy for the eradication of Helicobacter pylori, the main cause of duodenal
ulcers, as it is also successful in eradicating Helicobacter pylori even in
patients who have a metronidazole-resistant strain of Helicobacter pylori.

ABOUT HELICOBACTER PYLORI

The discovery in 1983 of the Helicobacter pylori organism was one of the
major advances in gastroenterology in recent decades, as it revolutionized the
approach to many upper gastrointestinal disorders. Helicobacter pylori is now
recognized as one of the most important causes of gastric and duodenal ulcers,
which affect at least 10% of the North American population at one point in
their lives. It is believed to cause a spectrum of diseases in humans,
including gastritis, ulcer disease (gastric and duodenal), gastric cancer, and
gastric lymphoma. Existing ulcer treatment regimens lead to high recurrence
rates. Gastric and duodenal ulcers recur respectively in approximately 40% to
80% of patients within a year after having received short-term treatment with
acid suppression therapy. Studies have shown that the recurrence rate of
peptic ulcers after one year is only 2% in patients in whom the organism has
been eradicated.

ABOUT AXCAN PHARMA

Axcan is a leading specialty pharmaceutical company specialized in the
field of gastroenterology. Axcan markets a broad line of prescription products
sold for the treatment of symptoms in a number of gastrointestinal diseases
and disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to Cystic Fibrosis.
Axcan's products are marketed by its own sales force in North America and the
European Union. Its common shares are listed on the Toronto Stock Exchange
under the symbol "AXP" and on the NASDAQ National Market under the symbol
"AXCA".

"Safe Harbor" statement under the Private Securities Litigation Reform
Act of 1995.

This release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. To the extent any
statements made in this release contain information that is not historical,
these statements are essentially forward looking and are often identified by
words such as "anticipate," "expect," "estimate," "intend," "project," "plan"
and "believe." Forward-looking statements are subject to risks and
uncertainties, including the difficulty of predicting FDA and other regulatory
approvals, acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials, the
regulatory environment, fluctuations in operating results, the protection of
our intellectual property and other risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission and the Canadian
securities regulators, including under the Canadian Multijurisdictional
Disclosure System.

The name HELIZIDE appearing in this press release is a trademark of Axcan
Pharma Inc. and its subsidiaries.



For further information: Isabelle Adjahi, Director, Investor Relations,
Axcan Pharma Inc., (450) 467-2600, ext. 2000; www.axcan.com;
Source: AXCAN PHARMA INC.;